AzaSite approval signals $19 million milestone payment

Article

The FDA has approved InSite Vision's New Drug Application (NDA) for AzaSite (azithromycin 1%) for the treatment of bacterial conjunctivitis.

The FDA has approved InSite Vision's New Drug Application (NDA) for AzaSite (azithromycin 1%) for the treatment of bacterial conjunctivitis.

AzaSite was shown to be safe and effective in two Phase III trials of more than 1,400 patients in the US and Latin America. The agent was administered twice daily for two days and then once daily for the next three days. The solution was found to offer clinically and statistically significant improvements in clinical resolution of symptoms and bacterial eradication compared with placebo.

AzaSite is formulated with DuraSite, InSite's patented drug delivery vehicle which is designed to enhance retention time of the antibiotic on the surface of the eye.

The approval has triggered a $19 million milestone payment from Inspire Pharmaceuticals, which has commercialization rights for AzaSite in the US and Canada.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.